老年女性非典型股骨骨折发病率随双膦酸盐暴露时间延长而增加
在加州北部接受口服双膦酸盐治疗的45-89岁女性中,非典型股骨骨折的年龄调整发病率随用药时间延长而升高,暴露≥8年时达112/10万人年。该趋势与加州南部报告一致,确认了双膦酸盐疗程相关的罕见但严重风险。
要点
- 94,542名女性中107例发生非典型股骨骨折,平均暴露6.6年。
- 暴露2-<4年年龄调整发病率为9/10万人年,≥8年峰值112/10万人年。
- 用药4-6年后非典型股骨骨折发病率明显上升,每2年类别翻倍余。
核心结论
- 非典型股骨骨折发病率在双膦酸盐暴露4-6年后明显增加,趋势与加州南部一致,确认了疗程相关的强烈风险。
研究设计与样本
- 在加州北部Kaiser Permanente,对2002-2014年启动口服双膦酸盐的45-89岁女性进行随访,共94,542名,观察非典型股骨骨折结局。
主要发现
- 94,542名女性中107例在用药期间或停药<1年内发生非典型股骨骨折,骨折时平均暴露6.6±3.0年,总供药天数5.7±2.8年。
- 暴露2-<4年者粗发病率和年龄调整发病率分别为18和9/10万人年,4-<6年和6-<8年者分别增加2倍余和5倍余。
- 暴露≥8年者粗发病率和年龄调整发病率峰值分别为196和112/10万人年。
- 非典型股骨骨折发病率随双膦酸盐暴露增加呈强相关,每2年类别翻倍余直至8-10年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In a northern California population of older women who were treated with oral bisphosphonate drugs, the incidence of atypical femur fracture, a rare complication of treatment, increased with longer duration of bisphosphonate exposure. These findings align with those previously reported in an independent southern California population. INTRODUCTION: The age-adjusted incidence of atypical femur fracture (AFF) reported in southern California increased with bisphosphonate (BP) exposure, ranging up to 113 per 100,000 person-years for 8-10-year exposure. This study examines the incidence of AFF in a northern California population. METHODS: Women age 45-89 years who initiated oral BP during 2002-2014 in Kaiser Permanente Northern California were followed for AFF outcome, defined by a primarily transverse diaphyseal femur fracture through both cortices, with focal periosteal/endosteal hypertrophy, minimal trauma, and minimal/no comminution. Total BP exposure was determined from dispensed prescriptions. The incidence of AFF, calculated for 2-year BP categories ranging from < 2 to > 10 years, was age-adjusted using the 2000 US Census. RESULTS: Among 94,542 women, 107 experienced an AFF during or < 1 year after BP cessation (mean exposure 6.6 ± 3.0 years and total days' supply 5.7 ± 2.8 years at AFF). A strong relationship between AFF incidence and increasing BP exposure was seen, more than doubling for each 2-year category until 8-10 years. Among women with 2- to < 4-year BP, the crude and age-adjusted incidence was 18 and 9 per 100,000 person-years but increased over 2- and 5-fold for women with 4- to < 6- and 6- to < 8-year BP, respectively. For those receiving ≥ 8-year BP, the crude and age-adjusted incidence peaked at 196 and 112 per 100,000 person-years exposure. CONCLUSION: Incidence of AFF increases markedly after 4-6 years of BP. These trends align with southern California and confirm a strong BP duration-related risk of this rare but serious event.
引用
- Lo JC, Grimsrud CD, Ott SM, et al. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019. PMID: 31555883. doi:10.1007/s00198-019-05112-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。